Similarly, a significant reduction in the mRNA level of SOD2 (Nayan et al. 2021; Park et al. 2016; Xia et al. 2016, 2018) as well as in relative gene expression of SOD1 and SOD2 (Krishnan et al. 2017) was reported in various animal models of MASLD compared to controls, respectively. This evidence concerns the gene SOD2 and metabolic dysfunction-associated steatotic liver disease.